
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 11, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg".
Filed with NSE · · 2 pages · English

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 11, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg".
Alembic Pharmaceuticals Limited on 6ix
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals